ABSTRACT
Target-tissue resistance to insulin characterizes type 2 diabetes mellitus. Resistin is produced and released from adipose tissue to serve endocrine functions likely involved in insulin resistance. Studies showed that resistin serum levels increase with obesity. The aim of the study is estimate and evaluates the current evidence of serum resistin in obese patients with type 2 diabetes and clarify its relation to glycemic control. The present study included 60 females obese patients who had type II diabetes, compared with 20 non-diabetic obese persons as control. The following parameters were done for every subject participating in the study: Fasting and postprandial blood glucose, lipid profile, serum insulin, serum resistin and calculation of HOMA-IR. There were highly significant increases in serum resistin, serum insulin and HOMA-IR in diabetic patients compared to control subjects. There were significant positive correlations between serum resistin and waist circumference, fasting and postprandial blood glucose, serum total cholesterol, serum LDL, serum insulin and HOMA-IR. This study suggests that resistin may have a role in obesity as well as in altering glucose metabolism leading to the progression of T2D. Further studies of the roles of resistin will shed new light on prevention and treatment of T2D and open a new field for the development of new drugs to improve insulin resistance